HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Immunogene therapy of tumors with a vaccine based on the ligand-binding domain of chicken homologous integrin beta3.

Abstract
The breaking of immune tolerance against angiogenesis-associated molecules should be a useful approach for cancer therapy by active immunity. We used chicken integrin beta3 as a model antigen to explore the feasibility of immunogene therapy of the tumors with a vaccine based on a single xenogeneic homologous gene, targeting the molecules associated with angiogenesis. To test this concept we constructed a plasmid DNA encoding the ligand-binding domain of chicken integrin beta3 (P-BD-C) and control vectors. We found that immunogene therapy of tumors with a vaccine based on the ligand-binding domain of chicken integrin beta3 (P-BD-C) was effective in both protective and therapeutic anti-tumor immunity in several tumor models in mice. Autoantibodies against integrin beta3 in sera of mice immunized with the ligand-binding domain of chicken integrin beta3 could be found by Western blot analysis and ELISA assay. The purified immunoglobulins were effective in the inhibition of endothelial cell proliferation in vitro, and in anti-tumor activity as well as in the inhibition of angiogenesis by adoptive transfer in vivo. The anti-tumor activity and the production of integrin beta3-specific autoantibodies (manifested by significantly elevated Ig G1 and Ig G2b) could be abrogated by the depletion of CD4+ T lymphocytes. These observations may provide a vaccine strategy for cancer therapy through the induction of the autoimmunity against the molecules associated with tumor growth in a cross-reaction with a single xenogeneic homologous gene and may be of importance in the further exploration of the applications of other xenogeneic homologous genes identified in human and other animal genome sequence projects in cancer therapy.
AuthorsYan-Yan Lou, Yu-Quan Wei, Li Yang, Xia Zhao, Ling Tian, You Lu, Yan-Jun Wen, Fen Liu, Mei-Juan Huang, Bin Kang, Fei Xiao, Jing-Mei Su, Qu-Ming He, Xing-Jiang Xie, Yun-qiu Mao, Song Lei, Ji-Yan Liu, Fen Lou, Li-qun Zhou, Feng Peng, Yu Jiang, Bing Hu
JournalImmunological investigations (Immunol Invest) Vol. 31 Issue 1 Pg. 51-69 (Feb 2002) ISSN: 0882-0139 [Print] England
PMID11990463 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Autoantibodies
  • Cancer Vaccines
  • Integrin beta3
  • Ligands
  • Vaccines, DNA
Topics
  • Animals
  • Autoantibodies (immunology)
  • CD4-Positive T-Lymphocytes (immunology)
  • COS Cells
  • Cancer Vaccines (immunology)
  • Chick Embryo
  • Chlorocebus aethiops
  • Integrin beta3 (genetics, immunology)
  • Ligands
  • Mice
  • Neovascularization, Pathologic (immunology)
  • Vaccination
  • Vaccines, DNA (immunology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: